Related Experiment Video
Updated: Oct 1, 2026

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
Published on: August 18, 2008
Heterozygous Atypical Cholinesterase: Management During ECT
John P. Riesenman1, Rano T. Mathew
1Department of Psychiatry, Loma Linda University School of Medicine, Loma Linda, California, USA.
Abstract:
A 70-year old woman developed prolonged apnea during an initial administration of electroconvulsive therapy (ECT) with succinylcholine. Because of the duration of apnea, she was suspected of having a heterozygous type of atypical cholinesterase. Subsequent therapies were administered with a reduced dose of succinylcholine. Prolonged apnea did not recur.
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Alzheimer's Disease: Treatment